These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 19135943)

  • 1. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy.
    Behrendt CE; Rosenthal J; Bolotin E; Nakamura R; Zaia J; Forman SJ
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):54-60. PubMed ID: 19135943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Factors Associated with Survival Following Ganciclovir Prophylaxis through Day +100 in Cytomegalovirus At-Risk Pediatric Allogeneic Stem Cell Transplantation Recipients: Development of Cytomegalovirus Viremia Associated with Significantly Decreased 1-Year Survival.
    Klejmont LM; Mo X; Milner J; Harrison L; Morris E; van de Ven C; Cairo MS
    Transplant Cell Ther; 2024 Jan; 30(1):103.e1-103.e8. PubMed ID: 37806447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.
    Schmidt-Hieber M; Tridello G; Ljungman P; Mikulska M; Knelange N; Blaise D; Socié G; Volin L; Blijlevens N; Fegueux N; Yakoub-Agha I; Forcade E; Maertens J; Chevallier P; Passweg J; Cornelissen J; Russell N; Craddock C; Bourhis JH; Marchand T; Reményi P; Cahn JY; Michallet M; Montoto S; Kröger N; Glaß B; Styczynski J
    Ann Hematol; 2019 Jul; 98(7):1755-1763. PubMed ID: 30993417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation.
    Ljungman P; Brand R; Hoek J; de la Camara R; Cordonnier C; Einsele H; Styczynski J; Ward KN; Cesaro S;
    Clin Infect Dis; 2014 Aug; 59(4):473-81. PubMed ID: 24850801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation.
    Jaing TH; Chang TY; Chen SH; Wen YC; Yu TJ; Lee CF; Yang CP; Tsay PK
    Medicine (Baltimore); 2019 Jan; 98(4):e14172. PubMed ID: 30681583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation.
    Styczynski J; Tridello G; Gil L; Ljungman P; Hoek J; Iacobelli S; Ward KN; Cordonnier C; Einsele H; Socie G; Milpied N; Veelken H; Chevallier P; Yakoub-Agha I; Maertens J; Blaise D; Cornelissen J; Michallet M; Daguindau E; Petersen E; Passweg J; Greinix H; Duarte RF; Kröger N; Dreger P; Mohty M; Nagler A; Cesaro S
    J Clin Oncol; 2016 Jul; 34(19):2212-20. PubMed ID: 27091716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.
    Guglieri-Lopez B; Perez-Pitarch A; Garcia-Cadenas I; Gimenez E; Barba P; Rabella N; Hernandez-Boluda JC; Fox L; Valcarcel D; Esquirol A; Ferriols-Lisart R; Sierra J; Solano C; Navarro D; Martino R; Piñana JL
    Biol Blood Marrow Transplant; 2019 May; 25(5):1022-1030. PubMed ID: 30639821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Leukemia.
    Inagaki J; Noguchi M; Kurauchi K; Tanioka S; Fukano R; Okamura J
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):300-306. PubMed ID: 26371373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients.
    Camacho-Bydume C; Mauguen A; Rodriguez-Sanchez MI; Klein E; Kernan NA; Prockop S; Boelens JJ; Papanicolaou GA; Cancio M
    Cytotherapy; 2022 Apr; 24(4):428-436. PubMed ID: 35042670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT.
    Schmidt-Hieber M; Labopin M; Beelen D; Volin L; Ehninger G; Finke J; Socié G; Schwerdtfeger R; Kröger N; Ganser A; Niederwieser D; Polge E; Blau IW; Mohty M
    Blood; 2013 Nov; 122(19):3359-64. PubMed ID: 24037724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT.
    Cesaro S; Crocchiolo R; Tridello G; Knelange N; Van Lint MT; Koc Y; Ciceri F; Gülbas Z; Tischer J; Afanasyev B; Bruno B; Castagna L; Blaise D; Mohty M; Irrera G; Diez-Martin JL; Pierelli L; Pioltelli P; Arat M; Delia M; Fagioli F; Ehninger G; Aljurf M; Carella AM; Ozdogu H; Mikulska M; Ljungman P; Nagler A; Styczynski J
    Bone Marrow Transplant; 2018 Apr; 53(4):422-430. PubMed ID: 29330396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis.
    Ljungman P; Brand R; Einsele H; Frassoni F; Niederwieser D; Cordonnier C
    Blood; 2003 Dec; 102(13):4255-60. PubMed ID: 12933590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation.
    Mariotti J; Maura F; Spina F; Roncari L; Dodero A; Farina L; Montefusco V; Carniti C; Sarina B; Patriarca F; Rambaldi A; Onida F; Olivieri A; Zallio F; Corradini P
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):885-90. PubMed ID: 24583412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study.
    Junghanss C; Boeckh M; Carter RA; Sandmaier BM; Maris MB; Maloney DG; Chauncey T; McSweeney PA; Little MT; Corey L; Storb R
    Blood; 2002 Mar; 99(6):1978-85. PubMed ID: 11877269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality.
    Matthes-Martin S; Lion T; Aberle SW; Fritsch G; Lawitschka A; Bittner B; Frommlet F; Gadner H; Peters C
    Bone Marrow Transplant; 2003 May; 31(9):803-8. PubMed ID: 12732888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes.
    Dalle JH; Balduzzi A; Bader P; Lankester A; Yaniv I; Wachowiak J; Pieczonka A; Bierings M; Yesilipek A; Sedlaçek P; Ifversen M; Sufliarska S; Toporski J; Glogova E; Poetschger U; Peters C
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1848-1855. PubMed ID: 29772352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.